Literature DB >> 29514037

Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.

Satish K Garg1, Paul Strumph2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29514037     DOI： 10.1056/NEJMc1800394

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

Authors:  John B Buse; Satish K Garg; Julio Rosenstock; Timothy S Bailey; Phillip Banks; Bruce W Bode; Thomas Danne; Jake A Kushner; Wendy S Lane; Pablo Lapuerta; Darren K McGuire; Anne L Peters; John Reed; Sangeeta Sawhney; Paul Strumph
Journal:  Diabetes Care       Date:  2018-06-24       Impact factor: 19.112

Review 2.  SGLT inhibitor adjunct therapy in type 1 diabetes.

Authors:  Rory J McCrimmon; Robert R Henry
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

3.  Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.

Authors:  Thomas Danne; Jeremy Pettus; Andrea Giaccari; Bertrand Cariou; Helena Rodbard; Stuart A Weinzimer; Mireille Bonnemaire; Sangeeta Sawhney; John Stewart; Stella Wang; Rita de Cassia Castro; Satish K Garg
Journal:  Diabetes Technol Ther       Date:  2019-09       Impact factor: 6.118

4.  Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.

Authors:  Claire Baker; Suman Wason; Phillip Banks; Sangeeta Sawhney; Anna Chang; Thomas Danne; Diane Gesty-Palmer; Jake A Kushner; Darren K McGuire; Frank Mikell; Mark O'Neill; Anne L Peters; Paul Strumph
Journal:  Diabetes Obes Metab       Date:  2019-08-01       Impact factor: 6.577

Review 5.  Adipose tissue, systematic inflammation, and neurodegenerative diseases.

Authors:  Ana Paula de A Boleti; Pedro Henrique de O Cardoso; Breno Emanuel F Frihling; Patrícia Souza E Silva; Luiz Filipe R N de Moraes; Ludovico Migliolo
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

6.  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects.

Authors:  Xuemei He; Xin Gao; Panpan Xie; Yuan Liu; Wenjing Bai; Yue Liu; Aixin Shi
Journal:  Drug Des Devel Ther       Date:  2022-09-06       Impact factor: 4.319

7.  Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.

Authors:  Bruce W Bode; Eda Cengiz; R Paul Wadwa; Phillip Banks; Thomas Danne; Jake A Kushner; Darren K McGuire; Anne L Peters; Paul Strumph; Sangeeta Sawhney
Journal:  Diabetes Technol Ther       Date:  2021-01       Impact factor: 6.118

Review 8.  Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.

Authors:  Amber L Beitelshees; Bruce R Leslie; Simeon I Taylor
Journal:  Diabetes       Date:  2019-06       Impact factor: 9.461

9.  Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.

Authors:  David R Powell; Brian Zambrowicz; Linda Morrow; Carine Beysen; Marcus Hompesch; Scott Turner; Marc Hellerstein; Phillip Banks; Paul Strumph; Pablo Lapuerta
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.